Olomoucine II

CDK抑制剂（Cdk1、-2、-4、-7和-9的IC50分别为7.6、0.1、19.8、0.45和0.06µM）；对其他10种激酶中的CDK具有选择性（所有激酶的IC50均=>100µM），但可抑制ERK2（IC50=32µM）和ABCB1（IC50=6.4µM）；可抑制多种癌细胞的增殖，包括表达野生型p53或突变型p53的癌细胞（平均IC50分别为7.4和10.1µM）；可抑制HSV-1、HSV-2、痘苗病毒、Ad4和人类CMV的复制（IC50分别为5、4.7、3.8、2.4、3.2µM）。A CDK inhibitor (IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 µM for Cdk1, -2, -4, -7, and -9, respectively); selective for CDKs over 10 additional kinases (IC50s = >100 µM for all) but does inhibit ERK2 (IC50 = 32 µM) and ABCB1(IC50 = 6.4 µM); inhibits proliferation of a variety of cancer cells, including those expressing wild-type p53 or mutant p53 (mean IC50s = 7.4 and 10.1 µM, respectively); inhibits replication of HSV-1, HSV-2, vaccinia virus, Ad4, and human CMV (IC50s = 5, 4.7, 3.8, 2.4, 3.2 µM, respectively).分子式C19H26N6O2分子量370.5OC[C@H](NC1=NC(NCC2=C(O)C=CC=C2)=C3N=CN(C(C)C)C3=N1)CC